<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574105</url>
  </required_header>
  <id_info>
    <org_study_id>12-37</org_study_id>
    <nct_id>NCT01574105</nct_id>
  </id_info>
  <brief_title>Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients</brief_title>
  <official_title>Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood is anticoagulated using a drug named heparin during open-heart surgery to allow it to
      safely pass through the heart-lung machine which pumps the blood throughout the body during
      the surgery. Each patient is given the heparin they need for their surgery. This means some
      patients receive more or less heparin than other patients. In this study, the investigators
      will be evaluating the current anticoagulation protocol for open heart surgery in use at the
      Royal University Hospital. The goal of this project is to compare patients who require and
      receive more heparin for proper anticoagulation to those patients who require and receive
      less heparin.

      Open-heart surgery will proceed according to the standard hospital protocol. All research
      participants will be treated according to standard post-open heart surgery protocol in the
      ICU. This will include measurement of blood loss by keeping track of chest tube outputs and
      administration of blood transfusions.

      This study focuses on Saskatoon Health Region patients having open heart surgery in terms of
      the protocol for anticoagulation and blood transfusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study examines heparin doses of patients having cardiopulmonary bypass supported surgery
      in terms of their sensitivity and resistance to heparin which is the standard anticoagulant
      used. The investigators use the Heparin Management System, an analyser that performs a
      heparin dose response test. In this test, a patient's whole blood is mixed with increasing
      amounts of heparin to determine the required dose to achieve a set level of anticoagulation.
      Patients who are found to resistant to heparin and needing a higher dose are thought by some
      to bleed more post operatively. It is my view that when the patient is given the correct
      amount of heparin which is then reversed by the correct amount of protamine (the reversal
      agent) the bleeding is not determined by heparin dose.

      Hypothesis statement: Higher doses of heparin do not cause increased postoperative bleeding
      and transfusion events in the postoperative CPB patient.

      Purposes of the Study

        1. Compare heparin sensitive and resistant patients in terms of postoperative bleeding and
           transfusion events.

        2. Determine the incidence of heparin sensitivity or resistance in patients.

        3. Identify preoperative factors that lead to heparin resistance or sensitivity in
           patients.

        4. Using the Heparin Dose Response test in determining heparin resistant and sensitive
           patients.

        5. Examination of anticoagulation protocol for open-heart surgery.

        6. Effect of preoperative antiplatelet and anticoagulant therapy on perioperative care.

        7. Use routine laboratory tests and values as well as common clinically available values in
           the conduct of the study so that results would be clinically relevant.

      This is a prospective observational study. Patients will be divided into two groups dependant
      upon the results of their heparin dose response test; sensitive or resistant. Two groups of
      thirty will be selected to achieve 90% power at the 0.025 level of significance using a
      one-sided two-sample t-test.

      The primary investigator will collect all data and submit the means to the statistician.
      Based on anecdotal experience the investigators expect there will be no difference between
      the two groups in terms of chest tube losses and transfusion events post-operatively.

      This work is quite relevant to the investigators daily practice. Every open heart patient is
      anticoagulated with heparin and bleeds post operatively. The investigators goal is a
      reproducibly safe anticoagulation level and an acceptable level of chest tube losses. This
      translates to getting patients out of the operating room in a timely fashion and minimizing
      transfusion events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chest Tube Losses</measure>
    <time_frame>Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)</time_frame>
    <description>Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion Events</measure>
    <time_frame>Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)</time_frame>
    <description>Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">66</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Heparin Resistant</arm_group_label>
    <description>Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin Sensitive</arm_group_label>
    <description>Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        On the date of surgery, the patient would be brought to the operating room. The first blood
        sample would be drawn prior to heparinization. This would include analysis for Activated
        Clotting Time, Heparin Concentration/Heparin Dose Response, antithrombin and
        Thrombelastograph. During this first sampling interval, the patient's Heparin Sensitivity
        or Resistance is determined by Heparin Dose Response (slope). The following values would
        determine which one of the two study groups the patient would be assigned:

          -  Sensitive to heparin: at or above 90 seconds/unit/millilitre

          -  Resistant to heparin: below 89 seconds/unit/millilitre
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective or urgent CABG of two to six vessels.

        Exclusion Criteria:

          -  Preoperative:

          -  Hemoglobin of less than 110grams/Litre

          -  Under 18 years of age

          -  Mass less than 75 kilograms

          -  Presence of an intra-aortic balloon pump

          -  Emergency surgery, requiring operative intervention within 24 hours of consultation to
             the cardiac surgery team

          -  Need for cardiac surgical intervention in addition to planned CABG (with the exception
             of patent foramen ovale closure)

          -  Ejection fraction of less than 50%, as determined by echocardiogram or angiography

          -  Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg

          -  Presence of infectious endocarditis

          -  Hepatic failure with impaired liver function, including INR greater than 1.5 Known
             diagnosed bleeding disorder

          -  History of heparin induced thrombocytopenia and thrombosis

          -  Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with
             urine output less than 10millilitres/hour

          -  Allergy to tranexamic acid

          -  Pregnancy

        Intraoperative:

          -  Discovery of infectious endocarditis

          -  Need for cardiac surgical intervention in addition to planned coronary CABG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W Rosin, MPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saskatoon Health Region</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7S 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <results_first_submitted>June 18, 2013</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2014</results_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Mark Rosin</investigator_full_name>
    <investigator_title>Senior Clinical Perfusionist</investigator_title>
  </responsible_party>
  <keyword>Heparin Dose</keyword>
  <keyword>Heparin Resistance</keyword>
  <keyword>Chest Tube Losses</keyword>
  <keyword>Transfusion Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Began May 1, 2012 Completed January 15, 2013 Patients identified in preadmission clinic or ward.</recruitment_details>
      <pre_assignment_details>Exclusion criteria included: renal failure, liver dysfunction, baseline INR &gt;1.5, clotting factor deficiencies, intra-aortic balloon pump therapy, emergency surgery, pregnancy, ejection fraction less than 50%, age less than 18 years, pulmonary hypertension infectious endocarditis, and history of heparin induced thrombocytopenia.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Heparin Resistant</title>
          <description>Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.</description>
        </group>
        <group group_id="P2">
          <title>Heparin Sensitive</title>
          <description>Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Heparin Resistant</title>
          <description>Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.</description>
        </group>
        <group group_id="B2">
          <title>Heparin Sensitive</title>
          <description>Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="9.8"/>
                    <measurement group_id="B2" value="67.8" spread="9.4"/>
                    <measurement group_id="B3" value="67.6" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Chest Tube Losses</title>
        <description>Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.</description>
        <time_frame>Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heparin Resistant</title>
            <description>Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Heparin Sensitive</title>
            <description>Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Chest Tube Losses</title>
          <description>Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.</description>
          <units>millilters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726" spread="371"/>
                    <measurement group_id="O2" value="781" spread="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the analysis of the patient characteristics Wilcoxon, Chi-square and Fischerâ€™s exact tests were used. An upper bound of a two-sided 95% confidence interval (CI) of the mean difference between resistant and sensitive groups for all values of chest tube losses was computed by analysis of covariance (ANCOVA), and compared with pre-specified noninferiority limits. Covariates in the ANCOVA model included patient characteristics differing between two groups with a p-value &lt;0.1.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample sizes of 26 in heparin resistant group and 26 in heparin sensitive group achieve 90% power at the 0.025 level of significance to detect a non-inferiority using a one-sided two-sample t-test, assuming a noninferiority margin is 200 milliliters in the postoperative chest tube loss.</non_inferiority_desc>
            <p_value>&lt;0.1</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transfusion Events</title>
        <description>Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.</description>
        <time_frame>Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heparin Resistant</title>
            <description>Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Heparin Sensitive</title>
            <description>Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion Events</title>
          <description>Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0.02" upper_limit="0.58"/>
                    <measurement group_id="O2" value="16" lower_limit="0.02" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Heparin Resistant</title>
          <description>Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.</description>
        </group>
        <group group_id="E2">
          <title>Heparin Sensitive</title>
          <description>Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Rosin</name_or_title>
      <organization>Saskatoon Health Region</organization>
      <phone>306-655-2128</phone>
      <email>mark.rosin@sasktoonhealthregion.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

